Two Sigma Investments LP Sells 24,214 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Two Sigma Investments LP lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 21.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 87,486 shares of the company's stock after selling 24,214 shares during the quarter. Two Sigma Investments LP owned 0.11% of IDEXX Laboratories worth $36,170,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. Hurley Capital LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth about $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth about $30,000. Colonial Trust Co SC raised its position in IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares during the period. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $38,000. Finally, Itau Unibanco Holding S.A. grew its position in shares of IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after acquiring an additional 81 shares during the period. Institutional investors own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IDXX. Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. Stifel Nicolaus increased their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Finally, Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $536.00.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director now directly owns 1,801 shares in the company, valued at $922,724.34. The trade was a 41.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded down $3.26 during trading hours on Monday, reaching $501.57. The company had a trading volume of 443,606 shares, compared to its average volume of 651,454. The firm has a market cap of $40.34 billion, a PE ratio of 47.01, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $530.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a fifty day simple moving average of $440.69 and a 200 day simple moving average of $434.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.71 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.